Canada markets closed
  • S&P/TSX

    -111.39 (-0.52%)
  • S&P 500

    +8.31 (+0.18%)
  • DOW

    +15.73 (+0.04%)

    +0.0000 (+0.00%)

    -0.20 (-0.24%)

    -3,157.67 (-4.02%)
  • CMC Crypto 200

    -32.61 (-2.17%)

    +0.40 (+0.02%)
  • RUSSELL 2000

    -16.56 (-0.72%)
  • 10-Yr Bond

    -0.0160 (-0.98%)
  • NASDAQ futures

    -6.00 (-0.04%)

    +0.74 (+4.86%)
  • FTSE

    +54.80 (+0.76%)
  • NIKKEI 225

    -98.17 (-0.34%)

    -0.0003 (-0.04%)

Nonmuscle Invasive Bladder Cancer Pipeline Insight Report 2021: Comprehensive Insights About 30+ Companies and 30+ Pipeline Drugs -

·4 min read

DUBLIN, September 28, 2021--(BUSINESS WIRE)--The "Nonmuscle Invasive Bladder Cancer - Pipeline Insight, 2021" clinical trials has been added to's offering.

This Nonmuscle invasive bladder cancer - Pipeline Insight, 2021 provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Nonmuscle invasive bladder cancer pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nonmuscle invasive bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Nonmuscle invasive bladder cancer.

Nonmuscle invasive bladder cancer Emerging Drugs Chapters

This segment of the Nonmuscle invasive bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nonmuscle invasive bladder cancer Emerging Drugs

UGN-102: UroGen Pharma

UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Nonmuscle invasive bladder cancer.

Sasanlimab: Pfizer

Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells. PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. Pfizer is developing PF-06801591 for the treatment of Non-muscle Invasive Bladder Cancer and is currently in phase III stage of development.

Major Players in Nonmuscle invasive bladder cancer

There are approx. 30+ key companies which are developing the therapies for Nonmuscle invasive bladder cancer. The companies which have their Nonmuscle invasive bladder cancer drug candidates in the most advanced stage, i.e. Phase III include, UroGen Pharma.


This report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Nonmuscle invasive bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nonmuscle invasive bladder cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nonmuscle invasive bladder cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonmuscle invasive bladder cancer drugs.

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Nonmuscle invasive bladder cancer drugs?

  • How many Nonmuscle invasive bladder cancer drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nonmuscle invasive bladder cancer?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nonmuscle invasive bladder cancer therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Nonmuscle invasive bladder cancer and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • UroGen Pharma

  • CG Oncolgy

  • Sasanlimab

  • Sesen Bio

  • Theralase Technologies

  • Asieris Pharmaceuticals

  • Hamlet Pharma

  • AstraZeneca

  • Viralytics

  • ImmunityBio

  • Prokarium

  • Vaxiion Therapeutics

  • Janssen Pharmaceuticals

  • Abraxis Bioscience

  • LIPAC Oncology

  • Rapamycin Holdings

  • Incyte Corporation

  • Taizhou Hanzhong biomedical

Key Products

  • UGN-102

  • CG 0070

  • Pfizer

  • Vicineum

  • TLD-1433

  • APL-1202

  • Alpha1H

  • Durvalumab

  • CVA 21

  • Inbakicept

  • Vesibax

  • VAX-014

  • Balversa

  • ABI-009

  • TSD-001

  • eRapa

  • Pemigatinib

  • HX008

For more information about this clinical trials report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting